Eléments de l'association
|  |
List of bibliographic references
Number of relevant bibliographic references: 6.| Ident. | Authors (with country if any) | Title |
|---|---|---|
| 001168 | Christopher J. Edwards [Royaume-Uni] ; Andrew J K. Östör [Australie] ; Barbara Naisbett-Groet ; Patrick Kiely [Royaume-Uni] | Tapering versus steady-state methotrexate in combination with tocilizumab for rheumatoid arthritis: a randomized, double-blind trial. |
| 001F26 | Andra F. Negoescu [Royaume-Uni] ; Andrew J K. Östör [Royaume-Uni] | Refining the Management of Rheumatoid Arthritis: the Benefits of Subcutaneous Tocilizumab. |
| 002106 | Muhammad K. Nisar [Royaume-Uni] ; Aneesa Rafiq [Royaume-Uni] ; Andrew J K. Östör [Royaume-Uni] | Biologic therapy for inflammatory arthritis and latent tuberculosis: real world experience from a high prevalence area in the United Kingdom. |
| 003553 | Vivian P. Bykerk [États-Unis, Canada] ; Andrew J K. Östör [Royaume-Uni] ; José Alvaro-Gracia [Espagne] ; Karel Pavelka [République tchèque] ; José Andrés Román Ivorra [Espagne] ; Winfried Graninger [Autriche] ; William Bensen [Canada] ; Michael T. Nurmohamed [Pays-Bas] ; Andreas Krause [Allemagne] ; Corrado Bernasconi [Suisse] ; Andrea Stancati [Suisse] ; Jean Sibilia [France] | Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice |
| 003896 | Laura Campbell [Royaume-Uni] ; Chen Chen ; Shweta S. Bhagat ; Richard A. Parker ; Andrew J K. Östör | Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. |
| 004198 | Annabel Kuek [Royaume-Uni] ; Brian L. Hazleman [Royaume-Uni] ; Andrew J K. Östör [Royaume-Uni] | Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution |
| This area was generated with Dilib version V0.6.34. |  |